Brought to you by 
Janssen Biotech gets global rights to Astellas Pharma's ASP015K; terminated
07 Dec 2015
Executive Summary
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive global rights to Astellas Pharma Inc.’s ASP015K, an oral small-molecule JAK1 inhibitor for immune-mediated inflammatory diseases. The deal excludes Japan, where Astellas will continue to develop the compound independently.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen Biotech gets global rights to Astellas Pharma's ASP015K; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice